1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
Alvan B. Sandler, M.D.

Alvan B. Sandler, M.D.

Contact Address
Vanderbilt-Ingram Cancer Center
777 Preston Research Building
Nashville, TN, 372326307
Contact Phone
(615) 322-4967
Professional Affiliations
  1. Vanderbilt-Ingram Cancer Center
    Position held:  Medical Director
    Program:  Thoracic Oncology

  3. Vanderbilt-Ingram Cancer Center
    Position held:  Director
    Program:  anderbilt-Ingram Cancer Center Affiliate Network Program

  5. Vanderbilt-Ingram Cancer Center
    Position held:  Medical Oncologist

Expertise
  1. Kaposi's Sarcoma
  2. Non-Small Cell Lung Cancer
  3. Small Cell Lung Cancer
  4. Mesothelioma
  5. Soft Tissue Sarcoma
  6. Thymoma and Thymic Carcinoma
Education
  1. Rush Medical School, M.D.,  1987
  2. Yale-New Haven Hospital, Postgraduate Training
  3. Yale University School of Medicine, Yale University School of Medicine
Appointments
    Associate Professor of Medicine Vanderbilt University Medical Center Division of Hematology/Oncology  
Biography

Alan B. Sandler is Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center in Nashville, Tennessee. He also serves as the Medical Director of the Thoracic Oncology Program and the Director of the Vanderbilt-Ingram Cancer Center Affiliate Network (VICCAN), a partnership of community-based oncologists who offer patients clinical trials.

After earning a B.S. in Pharmacy (cum laude) at the University of Toledo in Ohio and an M.D. at Rush Medical College in Chicago, Dr. Sandler completed an internship and residency in Internal Medicine at Yale-New Haven Hospital and a Fellowship in Medical Oncology at the Yale University School of Medicine in New Haven, Connecticut. His academic honors include membership in Alpha Omega Alpha and Rho Chi, the medical and pharmaceutical honor societies.

He is an active member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group where he serves as the Co-Chair of the Thoracic Committee. Dr. Sandler currently serves as Chairman or Co-Chairman of several Phase I, II, and III studies focusing on the activity of single or combined chemotherapy drugs and/or combined treatments for lung, esophageal, sarcoma and refractory cancers. Dr. Sandler serves as a consultant to several pharmaceutical companies. In addition, he serves on the editorial boards of American Journal of Clinical Oncology, Clinical Lung Cancer and the Japanese Journal of Clinical Oncology, and is a reviewer for several journals including The New England Journal of Medicine, the Journal of Clinical Oncology, Cancer Investigations, Cancer Therapeutics, Cancer, the British Journal of Cancer, and the European Respiratory Journal. Dr. Sandler is the author or co-author of more than 100 published articles, book chapters, reviews, and abstracts involving the pharmacology and clinical activity of chemotherapy and novel non-chemotherapy agents over a broad spectrum of tumor types.

Mesothelioma and Lung Cancer Specialists at
Vanderbilt-Ingram Cancer Center

  • David Carbone, M.D., Ph.D. Harold L. Moses Chair in Cancer Research, Ingram Professor of Cancer Research, Director of Specialized Program of Research Excellence in Lung Cancer, Director of the Experimental Therapeutics Program
  • Kenneth Hande, M.D. Medical Oncologist, Director Fellowship Program
  • David Johnson, M.D. Medical Oncologist, Cornelius Abernathy Craig Professor of Medical and Surgical Oncology, Director Division of Hematology/Oncology
  • Eric Lambright, M.D. Surgical Director Lung Transplant, Thoracic Surgeon
  • Pierre Massion, M.D. Pulmonary and Critical Care Medicine Doctor
  • Joe Putnam, M.D. Thoracic Surgeon